ACST Stock – (NASDAQ: ACST) is actually giving an update on the use
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or maybe the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is actually giving an update on the usage of the “at the market” equity of its providing plan.
As previously disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and H.C. Wainwright & Co., LLC (collectively, the “Agents”), to put into practice an “at-the market” equity offering program under which Acasti may issue and market from time to time its common shares having an aggregate offering price of up to $75 million in the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the last distributions found on January twenty seven, 2021, Acasti granted an aggregate of 20,159,229 typical shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate gross proceeds to the Company of US$21.7 zillion. The ATM Shares had been offered at prevailing market rates averaging US$1.0747 a share. No securities had been offered throughout the facilities of the TSXV or perhaps, to the knowledge of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S-3 (No. 333 239538) as made effective on July seven, 2020, and the Sales Agreement. Pursuant to the Sales Agreement, a cash commission of 3.0 % on the aggregate yucky proceeds raised was paid to the Agents in connection with their services. As a consequence of the latest ATM sales, Acasti has a total of 200,119,659 typical shares issued and outstanding as of March 5, 2021.
The additional capital raised has strengthened Acasti’s balance sheet and often will provide the Company with more flexibility in its continuous review process to check out and evaluate strategic options.
Approximately Acasti – ACST Stock
Acasti is a biopharmaceutical innovator that has historically centered on the research, commercialization and development of prescription medications making use of OM3 greasy acids delivered both as totally free fatty acids and bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have substantial clinical evidence of safety as well as efficacy in lowering triglycerides in people with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being created for individuals with severe HTG.
Forward Looking Statements – ACST Stock
Statements of this press release that aren’t statements of current or historical fact constitute “forward-looking information” to the meaning of Canadian securities laws as well as “forward looking statements” to the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward looking statements involve known and unknown risks, uncertainties, and other unknown variables that might cause the actual results of Acasti to be materially different from historical results or from any later outcomes expressed or even implied by such forward looking statements. In addition to statements which explicitly describe these types of risks as well as uncertainties, people are actually urged to give some thought to statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or any other similar expressions to be forward-looking and uncertain. Readers are actually cautioned not to place undue reliance on these forward-looking statements, which speak simply as of the particular date of this particular press release. Forward-looking claims in this press release include, but are not limited to, info or statements concerning Acasti’s strategy, future operations and the review of its of strategic options.
The forward looking claims contained in this specific press release are expressly qualified in their entirety by this cautionary declaration, the “Special Note Regarding Forward-Looking Statements” section contained in Acasti’s latest annual report on Form 10-K and quarterly report on Form 10-Q, which are actually available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com as well as on the investor section of Acasti’s site at www.acastipharma.com. Most forward looking claims in this press release exist as of the day of this particular press release.
ACST Stock – Acasti doesn’t undertake to redesign any such forward-looking statements whether as a consequence of info that is brand new , future events or perhaps otherwise, except as needed by law. The forward-looking claims contained herein are also subject typically to assumptions and risks and uncertainties that are discussed from time to time in Acasti’s public securities filings with the Securities as well as The Canadian and exchange Commission securities commissions, including Acasti’s newest annual report on Form 10 K and quarterly report on Form 10 Q underneath the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is giving an update on the usage